Usefulness of the Post-Vascular Phase of Contrast-Enhanced Ultrasonography with Sonazoid in the Evaluation of Gross Types of Hepatocellular Carcinoma
Kinuyo Hatanaka(Union Hospital), Kazuomi Ueshima(Kindai University), Satoru Hagiwara(Kindai University Hospital), Hobyung Chung(Kindai University), Masahiro Takita(Kindai University), Masatoshi Kudo(Kindai University), Satoshi Kitai(Kindai University), Kanae Kudo, Yasunori Minami, Tatsuo Inoue, Tomoyuki Nagai(Tohoku University), Emi Ishikawa(Kyowa Chemical Industry (Japan)), Norihisa Yada(Kindai University), Seiji Haji(Kindai University), Taisuke Ueda(Kindai University), Sousuke Hayaishi(Kindai University), Kiyoshi Maekawa(Kindai University), Chie Tatsumi(Kindai University)
Cited by 32
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k